Sun Pharma
Search results
Built on the foundation of caring for life, Cipla ensures access to quality & affordable medicines through 1500+ products across various therapeutic categories.
Make every life thrive. You will be inspired by our purpose and pioneering spirit at Cipla. Growth, to us, is meaningful when it is holistic and has an impact beyond ourselves. Inspiring Pioneers. Championing Care. Nourishing Careers. Search jobs.
Cipla Limited (stylized as Cipla) is an Indian multinational pharmaceutical company headquartered in Mumbai. Cipla primarily focuses on developing medication to treat respiratory disease, cardiovascular disease, arthritis, diabetes, depression, and various other medical conditions.
Cipla is a leading pharmaceutical company that provides affordable medicine to patients across geographies. Over the last 8 decades, we have been fortifying our promise of ‘Caring for Life'.
Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the...
1 day ago · Cipla has “completely professionalised” over the last 10 years, said Cipla Managing Director and Global Chief Executive Umang Vohra, of a transformative journey undertaken even as two of its ...
1 day ago · Cipla Limited Stock Price Today, Live NSE Share Price: Get the latest Cipla Limited news, company updates, quotes, tips, historical charts, 52 week high low, market performance financial reports and many more at NSE India.
1 day ago · Discover the Cipla Stock Liveblog, your ultimate resource for real-time updates and insightful analysis on a prominent stock. Keep track of Cipla with the latest details, including: Last traded price 1487.0, Market capitalization: 119550.88, Volume: 2087, Price-to-earnings ratio 29.01, Earnings per share 51.05. Our comprehensive coverage combines fundamental and technical indicators to provide you with a comprehensive view of Cipla's performance. Stay informed about breaking news that can ...
5 days ago · Umang Vohra, managing director & global chief executive officer, Cipla, said, “AMR is an urgent and serious healthcare challenge that needs global attention. With the rising incidence of potentially-life threatening infections, there is a strong need for novel anti-infectives in the effective treatment of MDR infections. This partnership enhances Cipla’s commitment to AMR stewardship and strengthens our efforts to combat infectious diseases and deliver advanced, innovative therapies to ...
2 days ago · Cipla’s success in the US market is a significant growth driver. This success is attributed to new product launches, seasonal factors, and a strong market position in key assets.
